Treatment of hyperprolactinemic amenorrhea by intermittent administration of bromocryptine (CB 154). 1978

E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri

The results obtained with intermittent bromocryptine treatment from the fifth day after the beginning of menstruation until the second day after the basal temperature rise, in 14 women with hyperprolactinemic amenorrhea-galactorrhea and in whom menses had previously been induced by continuous treatment, are presented. All women had menses without reappearance of galactorrhea; serum FSH, LH, estradiol, and progesterone followed a normal physiologic trend. Only prolactin rose again in the second phase of the cycle, in which lower levels of progesterone were also found, but without any significant interference in the clinical and hormonal trend. It is stressed that administration of bromocryptine during the first part of the cycle might substitute for continuous administration, thereby reducing drug consumption and hence possible side-effects as well as the cost of treatment.

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D005687 Galactorrhea Excessive or inappropriate LACTATION in females or males, and not necessarily related to PREGNANCY. Galactorrhea can occur either unilaterally or bilaterally, and be profuse or sparse. Its most common cause is HYPERPROLACTINEMIA. Galactorrheas

Related Publications

E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
December 1975, Archiv fur Gynakologie,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
July 1977, Archiv fur Gynakologie,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
November 1983, Geburtshilfe und Frauenheilkunde,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
July 1994, Jikken dobutsu. Experimental animals,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
December 1977, Horumon to rinsho. Clinical endocrinology,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
June 1982, Journal of animal science,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
January 1981, International journal of fertility,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
December 1977, Horumon to rinsho. Clinical endocrinology,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
July 1983, Nihon Sanka Fujinka Gakkai zasshi,
E Polatti, and P F Bolis, and M F Ravagni-Probizer, and A Baruffini, and A Cavalleri
July 1977, Nederlands tijdschrift voor geneeskunde,
Copied contents to your clipboard!